FY2029 Earnings Estimate for FDMT Issued By HC Wainwright

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of 4D Molecular Therapeutics in a research note issued to investors on Monday, January 13th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($1.81) per share for the year. HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.89) per share.

Several other brokerages have also recently issued reports on FDMT. Morgan Stanley lowered their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a research note on Monday. Chardan Capital reissued a "buy" rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Leerink Partners dropped their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a research note on Monday. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $40.00 to $15.00 in a report on Monday. Finally, Royal Bank of Canada lowered their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating on the stock in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $38.56.

4D Molecular Therapeutics Stock Performance

Shares of FDMT traded up $0.16 during trading hours on Wednesday, hitting $5.04. 626,938 shares of the stock were exchanged, compared to its average volume of 784,338. The stock's 50-day moving average price is $6.87 and its two-hundred day moving average price is $11.77. 4D Molecular Therapeutics has a 12-month low of $4.68 and a 12-month high of $36.25. The company has a market cap of $232.99 million, a price-to-earnings ratio of -1.77 and a beta of 2.81.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new position in 4D Molecular Therapeutics in the third quarter worth approximately $40,000. Values First Advisors Inc. acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $57,000. Quest Partners LLC lifted its stake in shares of 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company's stock valued at $121,000 after purchasing an additional 5,745 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock worth $108,000 after purchasing an additional 3,922 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $108,000. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.